These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28985058)

  • 21. Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer's Disease.
    Sánchez-Arias JA; Rabal O; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; Ugarte A; Sáez E; Espelosin M; Ursua S; Haizhong T; Wei W; Musheng X; Garcia-Osta A; Oyarzabal J
    ACS Chem Neurosci; 2017 Mar; 8(3):638-661. PubMed ID: 27936591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclic GMP-mediated memory enhancement in the object recognition test by inhibitors of phosphodiesterase-2 in mice.
    Lueptow LM; Zhan CG; O'Donnell JM
    Psychopharmacology (Berl); 2016 Feb; 233(3):447-56. PubMed ID: 26525565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors.
    Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Haizhong T; Wei W; Musheng X; Garcia-Osta A; Oyarzabal J
    ACS Chem Neurosci; 2019 Mar; 10(3):1765-1782. PubMed ID: 30525452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacophore based virtual screening, molecular docking and biological evaluation to identify novel PDE5 inhibitors with vasodilatory activity.
    Mittal A; Paliwal S; Sharma M; Singh A; Sharma S; Yadav D
    Bioorg Med Chem Lett; 2014 Jul; 24(14):3137-41. PubMed ID: 24856068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.
    Sawant SD; Lakshma Reddy G; Dar MI; Srinivas M; Gupta G; Sahu PK; Mahajan P; Nargotra A; Singh S; Sharma SC; Tikoo M; Singh G; Vishwakarma RA; Syed SH
    Bioorg Med Chem; 2015 May; 23(9):2121-8. PubMed ID: 25801159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitors of blood platelet cAMP phosphodiesterase. 3. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives with enhanced aqueous solubility.
    Meanwell NA; Dennis RD; Roth HR; Rosenfeld MJ; Smith EC; Wright JJ; Buchanan JO; Brassard CL; Gamberdella M; Gillespie E
    J Med Chem; 1992 Jul; 35(14):2688-96. PubMed ID: 1321911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors.
    Ahmed WS; Geethakumari AM; Biswas KH
    Biomed Pharmacother; 2021 Feb; 134():111128. PubMed ID: 33348311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies.
    Di Pietro O; Viayna E; Vicente-García E; Bartolini M; Ramón R; Juárez-Jiménez J; Clos MV; Pérez B; Andrisano V; Luque FJ; Lavilla R; Muñoz-Torrero D
    Eur J Med Chem; 2014 Feb; 73():141-52. PubMed ID: 24389509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microwave-Assisted Synthesis of (Piperidin-1-yl)quinolin-3-yl)methylene)hydrazinecarbothioamides as Potent Inhibitors of Cholinesterases: A Biochemical and In Silico Approach.
    Munir R; Zia-Ur-Rehman M; Murtaza S; Zaib S; Javid N; Awan SJ; Iftikhar K; Athar MM; Khan I
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33513837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 8-(3-chloro-4-methoxybenzyl)-8H-pyrido[2,3-d]pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors.
    Sakamoto T; Koga Y; Hikota M; Matsuki K; Mochida H; Kikkawa K; Fujishige K; Kotera J; Omori K; Morimoto H; Yamada K
    Bioorg Med Chem Lett; 2015 Apr; 25(7):1431-5. PubMed ID: 25754491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and evaluation of N
    Pobsuk N; Paracha TU; Chaichamnong N; Salaloy N; Suphakun P; Hannongbua S; Choowongkomon K; Pekthong D; Chootip K; Ingkaninan K; Gleeson MP
    Bioorg Med Chem Lett; 2019 Jan; 29(2):267-270. PubMed ID: 30509781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives.
    de Los Ríos C; Egea J; Marco-Contelles J; León R; Samadi A; Iriepa I; Moraleda I; Gálvez E; García AG; López MG; Villarroya M; Romero A
    J Med Chem; 2010 Jul; 53(14):5129-43. PubMed ID: 20575555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
    Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Haizhong T; Wei W; Musheng X; Garcia-Osta A; Oyarzabal J
    Eur J Med Chem; 2018 Apr; 150():506-524. PubMed ID: 29549837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and synthesis of novel conformationally constrained 7,12-dihydrodibenzo[b,h][1,6] naphthyridine and 7H-Chromeno[3,2-c] quinoline derivatives as topoisomerase I inhibitors: In vitro screening, molecular docking and ADME predictions.
    Kardile RA; Sarkate AP; Borude AS; Mane RS; Lokwani DK; Tiwari SV; Azad R; Burra PVLS; Thopate SR
    Bioorg Chem; 2021 Oct; 115():105174. PubMed ID: 34314913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor.
    Mochida H; Takagi M; Inoue H; Noto T; Yano K; Fujishige K; Sasaki T; Yuasa K; Kotera J; Omori K; Kikkawa K
    Eur J Pharmacol; 2002 Dec; 456(1-3):91-8. PubMed ID: 12450574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FFPM, a PDE4 inhibitor, reverses learning and memory deficits in APP/PS1 transgenic mice via cAMP/PKA/CREB signaling and anti-inflammatory effects.
    Guo H; Cheng Y; Wang C; Wu J; Zou Z; Niu B; Yu H; Wang H; Xu J
    Neuropharmacology; 2017 Apr; 116():260-269. PubMed ID: 28065587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors.
    Kayık G; Tüzün NŞ; Durdagi S
    J Biomol Struct Dyn; 2017 Oct; 35(13):2830-2852. PubMed ID: 27581752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scaffold Repurposing Reveals New Nanomolar Phosphodiesterase Type 5 (PDE5) Inhibitors Based on Pyridopyrazinone Scaffold: Investigation of In Vitro and In Silico Properties.
    Amin KM; El-Badry OM; Abdel Rahman DE; Abdellattif MH; Abourehab MAS; El-Maghrabey MH; Elsaid FG; El Hamd MA; Elkamhawy A; Ammar UM
    Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and in vitro evaluation of new fluorinated quinoline derivatives with high affinity for PDE5: Towards the development of new PET neuroimaging probes.
    Liu J; Maisonial-Besset A; Wenzel B; Canitrot D; Baufond A; Chezal JM; Brust P; Moreau E
    Eur J Med Chem; 2017 Aug; 136():548-560. PubMed ID: 28544981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer's Disease.
    Sharma VK; Singh TG; Singh S
    Curr Drug Targets; 2020; 21(13):1371-1384. PubMed ID: 32718286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.